Dr. Gotto

Dr. Gotto is an uro-oncologist specializing in the management of urologic malignancies, including prostate cancer. After graduating from the University of British Columbia and receiving the Wesbrook Scholar designation and Hamber Scholarship in Medicine. He went on to complete a Fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York and received his Masters of Public Health from Harvard. He is a Clinical Associate Professor in the Departments of Surgery and Oncology at the University of Calgary.

Dr. Gotto received the Canadian Urological Association scholarship for his research into health outcomes reporting and synoptic data acquisition. He was awarded Calgary’s Top 40 Under 40 award, in part for his work founding CAMP – the Clinic for Advanced and Metastatic Prostate Cancer at the Prostate Cancer Centre.

Dr. Gotto is the Principal Investigator for several clinical trials in advanced prostate cancer at the Prostate Cancer Centre. He was the only investigator for ARAMIS in Western Canada, and has extensive experience using darolutamide in nmCRPC. He is also participating in DAROL as an investigator (DAROL: DARolutamide ObservationaL) study patients in nmCRPC patients.

He is a father to 4 yr old twins and an avid backcountry skier and mountain biker.

Additional Resources:

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer With Darolutamide

Summary Basis of Decision – Nubeqa – Health Canada

Darolutamide (Nubeqa) for Non-Metastatic Castration Resistant Prostate Cancer

Non-metastatic castration resistant prostate cancer treatment NUBEQA® (darolutamide) significantly improves overall survival with a favourable safety profile in men with non-metastatic prostate cancer